Aeglea BioTherapeutics (NasdaqGM: AGLE) is a biotechnology company developing enzyme-based treatments for patients with inborn errors of metabolism and cancer. The Company employs protein engineering to create more active enzymes with higher stability. Lead candidate AEB1102 is a pegylated human arginase I designed to deplete arginine in the blood. In the third quarter of 2016, Aeglea is planning to initiate a Phase I trial with AEB1102 in patients with arginase I deficiency, and is currently conducting a Phase I trial in patients with arginine-dependent cancer. Aeglea has a pipeline of additional candidates based on its biochemistry expertise and ability to engineer enzymes. The Company completed a $47.3 million IPO in April 2016 and is now trading under the ticker AGLE.